Ascendis Pharma A/S ASND
$252.73 −$3.23 (-1.26%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $252.73 0.00%
Open$255.44
Prev close$255.96
Day range$251.55 – $256.65
Volume602.9K
Market cap$16.63B
P/E (TTM)34.7
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026 · reported in EUR
Revenue€369.66M+73.0% YoY
Operating profit€124.58M+1,032.8% YoY
Net profit€73.97M+221.3% YoY
Diluted EPS€1.08+208.0% YoY
Free cash flow€186.03M+8,758.6% YoY
Operating cash flow€188.79M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin91.9%
Operating margin31.3%
Net margin72.9%
Return on equity132.2%
Return on assets49.0%
Return on invested capital69.9%
Current ratio2.89
Liabilities / assets38.2%
Cash & investments€964.36M
Total debt€447.81M
Net cash (debt)€516.56M
Free cash flow / sales43.1%
Where the revenue comes from
Quarter 2026/Q3
By business line
This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.
Income statement
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Total Revenue as Reported | €369.66M | €339.29M | €246.60M | €720.13M | €247.50M |
| Total Operating Revenue | €369.66M | €339.29M | €246.60M | €720.13M | €247.50M |
| Cost of Revenue | €28.31M | €27.66M | €17.52M | €94.92M | €23.60M |
| Gross Profit | €341.35M | €311.63M | €229.09M | €625.22M | €223.90M |
| Operating Expense | €216.77M | €91.16M | €204.27M | €761.49M | €217.46M |
| Selling and Admin Expenses | €145.14M | €171.68M | €145.23M | €448.04M | €135.00M |
| -General & Admin Expense | €145.14M | €171.68M | – | €448.04M | €135.00M |
| Research & Development | €69.93M | €75.89M | €59.04M | €303.62M | €78.15M |
| Depreciation & Amortization & Depletion | €1.71M | €1.66M | – | €9.82M | €4.31M |
| -Depreciation & Amortization | €1.71M | €1.66M | – | €9.82M | €4.31M |
| Operating Profit | €124.58M | €220.47M | €24.81M | -€136.27M | €6.44M |
| Net Non-Operating Interest Income (Expense) | -€4.39M | -€1.03M | -€62.74M | -€44.88M | €4.30M |
| Non-Operating Interest Income | €7.65M | €4.83M | €4.52M | €15.30M | €4.37M |
| Non-Operating Interest Expense | €12.04M | €14.17M | €67.26M | €80.65M | €20.54M |
| Other Income (Expense) | -€6.81M | €10.66M | -€10.25M | -€31.50M | -€37.45M |
| Gain on Sale of Security | €55,000.00 | €6.82M | – | -€47.81M | -€42.23M |
| Earnings from Equity Interest | -€6.87M | €3.84M | -€10.25M | €16.31M | €1.33M |
| Special Income (Charges) | €0.00 | €0.00 | – | – | – |
| -Less:Impairment of Capital Assets | €0.00 | €0.00 | – | – | – |
| Pretax Profit | €113.37M | €230.09M | -€48.18M | -€212.65M | -€26.71M |
| Tax | €39.40M | €23.12M | -€677.52M | €15.38M | €6.86M |
| Net Profit | €73.97M | €206.97M | €629.34M | -€228.03M | -€33.56M |
| Profit from Continuing Operations | €73.97M | €206.97M | €629.34M | -€228.03M | -€33.56M |
| Net Income to Parent Company | €73.97M | €206.97M | €629.34M | -€228.03M | -€33.56M |
| Net Income to Common Stockholders | €73.97M | €206.97M | €629.34M | -€228.03M | -€33.56M |
| Basic EPS | €1.13 | €3.22 | €10.20 | -€3.76 | -€0.55 |
| Diluted EPS | €1.08 | €2.83 | €9.75 | -€3.76 | -€0.55 |
| Other Operating Expenses | – | -€158.07M | – | – | – |
| Total Other Finance Costs | – | -€8.31M | – | -€20.47M | – |
Balance sheet
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Total Assets | €2.43B | €2.29B | €2.00B | €1.30B | €1.30B |
| Total Current Assets | €1.59B | €1.39B | €1.12B | €1.11B | €1.11B |
| Cash and Cash Equivalents & Short-Term Investments | €964.36M | €812.26M | €572.82M | €616.04M | €616.04M |
| -Cash and Cash Equivalents | €964.36M | €812.26M | €572.82M | €616.04M | €616.04M |
| Receivables | €254.42M | €224.10M | €196.61M | €157.70M | €157.70M |
| -Accounts Receivable | €225.84M | €206.51M | €178.68M | €141.33M | €141.33M |
| -Taxes Receivable | €11.89M | €1.99M | €1.26M | €1.78M | €1.78M |
| -Other Receivables | €16.68M | €15.60M | €16.67M | €14.58M | €14.58M |
| Prepaid Assets | €36.83M | €43.47M | €38.57M | €33.72M | €33.72M |
| Inventory | €331.35M | €310.58M | €314.34M | €301.53M | €301.53M |
| Total Non-Current Assets | €840.23M | €895.61M | €880.94M | €193.59M | €193.59M |
| Net PPE | €134.94M | €135.69M | €135.92M | €146.48M | €146.48M |
| Investments and Advances | €24.11M | €30.48M | €23.56M | €32.53M | €32.53M |
| -Long Term Equity Investment | €24.11M | €30.48M | €23.56M | €32.53M | €32.53M |
| Non Current Accounts Receivables | €25.64M | €26.49M | €27.37M | €10.87M | €10.87M |
| Goodwill and Other Intangible Assets | €3.66M | €3.68M | €3.69M | €3.71M | €3.71M |
| Non-Current Deferred Assets | €651.89M | €699.28M | €690.41M | – | – |
| Total Liabilities | €926.73M | €849.53M | €1.52B | €1.47B | €1.47B |
| Total Current Liabilities | €549.08M | €464.89M | €1.13B | €1.07B | €1.07B |
| Payables | €122.35M | €116.58M | €86.39M | €97.08M | €97.08M |
| -Accounts Payable | €109.72M | €103.92M | €78.59M | €90.66M | €90.66M |
| -Total Tax Payable | €12.64M | €12.66M | €7.81M | €6.43M | €6.43M |
| Short-Term Debt and Capital Lease Obligation | €70.15M | €65.43M | €510.56M | €486.53M | €486.53M |
| -Current Debt | €70.15M | €65.43M | €510.56M | €486.53M | €486.53M |
| Current Provisions | €265.17M | €221.41M | €176.65M | €166.40M | €166.40M |
| Current Deferred Liabilities | €3.89M | €2.78M | €5.36M | €4.94M | €4.94M |
| Other Current Liabilities | €87.52M | €58.69M | €347.80M | €314.44M | €314.44M |
| Total Non-Current Liabilities | €377.65M | €384.64M | €388.54M | €396.00M | €396.00M |
| Long Term Debt and Capital Lease Obligation | €377.65M | €384.64M | €386.11M | €385.25M | €385.25M |
| -Long Term Debt | €377.65M | €384.64M | €386.11M | €385.25M | €385.25M |
| Non-Current Deferred Liabilities | €0.00 | €0.00 | €2.44M | €10.75M | €10.75M |
| Total Equity | €1.50B | €1.44B | €487.97M | -€162.82M | -€162.82M |
| Stockholders' Equity | €1.50B | €1.44B | €487.97M | -€162.82M | -€162.82M |
| Capital Stock | €8.91M | €8.89M | €8.38M | €8.32M | €8.32M |
| -Common Stock | €8.91M | €8.89M | €8.38M | €8.32M | €8.32M |
| Other Equity Interests | €1.49B | – | €479.59M | -€171.14M | -€171.14M |
| Additional Paid-In Capital | – | €3.30B | – | – | – |
| Retained Earnings | – | -€1.88B | – | – | – |
| Less: Treasury Stock | – | -€69,000.00 | – | – | – |
| Gains/Losses Not Affecting Retained Earnings | – | €6.16M | – | – | – |
| -Gross PPE | – | – | – | €222.90M | €222.90M |
| -Accumulated Depreciation | – | – | – | -€76.42M | -€76.42M |
| -Goodwill | – | – | – | €3.50M | €3.50M |
| -Other Intangible Assets | – | – | – | €215,000.00 | €215,000.00 |
Cash flow
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Operating Cash Flow | €188.79M | €281.68M | -€7.72M | €53.90M | €73.40M |
| Net cash flow from continuing operations | €188.79M | €281.68M | -€7.72M | €53.90M | €73.40M |
| Net Income from Continuing Operations | €73.97M | €206.97M | €629.34M | -€228.03M | -€33.56M |
| Gain/Loss from Continuing Operations | €6.87M | -€3.82M | €10.25M | -€16.31M | -€1.33M |
| Depreciation & Depletion & Amortization | €4.64M | €4.57M | €4.22M | €17.70M | €4.82M |
| Deferred Tax | €39.40M | €23.12M | -€677.52M | €15.38M | €6.86M |
| Other Non-Cash Items | €3.87M | -€8.27M | €62.10M | €87.06M | €35.30M |
| Change in Working Capital | €89.87M | -€7.39M | -€66.82M | €70.96M | €39.86M |
| -Change in Receivables | -€18.31M | -€24.67M | -€36.38M | €15.59M | -€9.55M |
| -Change in Inventory | -€20.78M | €3.77M | -€12.81M | -€5.92M | €501,000.00 |
| -Change in Prepaid Assets | €6.65M | -€4.64M | -€4.85M | -€6.05M | -€4.32M |
| -Change in Payables and Accrued Expense | €27.75M | €29.71M | -€21.05M | -€10.37M | €22.72M |
| -Change In Other Working Capital | €94.56M | -€11.56M | €8.27M | €77.72M | €30.51M |
| Net cash flow from investing | -€2.10M | -€2.85M | -€6.75M | -€8.49M | -€3.39M |
| Net Cash Flow from Continuing Investing Activities | -€2.10M | -€2.85M | -€6.75M | -€8.49M | -€3.39M |
| Net PPE Purchase and Sale | -€2.76M | -€11.91M | €959,000.00 | -€8.49M | -€3.39M |
| Net Other Investing Changes | €662,000.00 | €9.05M | -€7.71M | – | – |
| Financing Cash Flow | -€38.47M | -€46.12M | -€36.83M | €36.33M | €8.52M |
| Net Cash Flow from Continuing Financing Activities | -€38.47M | -€46.12M | -€36.83M | €36.33M | €8.52M |
| Net Issuance Payments Of Debt | -€9.03M | -€8.14M | -€8.58M | -€21.96M | -€6.83M |
| Net Common Stock Issuance | -€52.43M | -€51.56M | -€51.86M | -€17.40M | €0.00 |
| Proceeds from Stock Option Exercised | €22.98M | €18.46M | €31.63M | €87.08M | €15.35M |
| Net Other Financing Charges | €0.00 | -€4.89M | -€8.02M | -€11.40M | €0.00 |
| Ending Cash Balance | €964.36M | €812.26M | €572.82M | €616.04M | €616.04M |
| Net Change in Cash | €148.22M | €232.71M | -€51.31M | €81.74M | €78.52M |
| Beginning Cash Balance | €812.26M | €572.82M | €616.04M | €559.54M | €539.09M |
| Effect of Exchange Rate Changes | €3.89M | €6.73M | €8.09M | -€25.24M | -€1.58M |
| Free Cash Flow | €186.03M | €270.73M | -€7.72M | €45.41M | €70.01M |
| Net Investment Purchase and Sale | – | – | – | €0.00 | €0.00 |
No comments yet — be the first to weigh in on ASND.
Sign in to join the discussion.